BioNTech
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Recent price momentum is -21.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth B-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | -45.1% | Better than 1% |
| Net income CAGR (3Y) | 294.1% | Better than 99% |
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 77.6% | Better than 89% |
| Operating margin | -22.3% | Better than 12% |
| Net margin | -39.6% | Better than 9% |
| Return on equity | -5.9% | Better than 22% |
| Return on invested capital | -5.7% | Better than 21% |
Momentum C-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -30.5% | Better than 17% |
| 6-month return | -12.1% | Better than 37% |
| 12-month return (ex latest month) | -6.2% | Better than 26% |
| Distance below 52-week high | 34.7% | Better than 35% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 7.5x | Better than 91% |
| Debt to assets | 1.2% | Better than 91% |
| Interest coverage | -73.0x | Better than 6% |
| Free cash flow / net income | 501.5% | Better than 93% |
Analyst View B
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 75.0% | Better than 51% |
| Upside to average target | 47.4% | Better than 65% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 81.38
- Open
- 80.82
- Day range
- 80.27 - 82.87
- Avg price
- 80.93
- Volume
- 1.71M
- Turnover
- 138.41M
- Turnover ratei
- 1.61%
- Volume ratioi
- 1.47
- Amplitudei
- 3.19%
- 52-week rangei
- 79.52 - 124.00
Valuation
- P/Ei
- -15.71
- P/E (TTM)i
- -12.55
- P/Bi
- 1.03
- EPSi
- -5.15
- Book value / shi
- 78.35
- Net profit
- -1.28B
- Net assets
- 19.42B
Share structure
- Market cap
- 20.07B
- Float capi
- 8.58B
- Shares out
- 247.93M
- Float sharesi
- 106.00M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2019-10-10
34.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-24.79M net over the window
Short interest
- Shares short
- 2.25M
- % of floati
- 0.89%
- Days to coveri
- 2.15
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of BioNTech (BNTX)?
BioNTech last traded at 80.96. This page shows a periodic quote snapshot. Check the displayed quote time.
What is BioNTech's market cap?
About 20.07B.
What is the P/E ratio of BioNTech?
The trailing twelve-month P/E is -12.55. The Valuation tab shows it against the stock's own five-year range.
Does BioNTech pay a dividend?
BioNTech does not currently pay a regular dividend.
Is BioNTech a buy according to analysts?
The consensus of 16 analysts is a Buy rating, with an average 12-month price target of 119.33, which implies 47.4% upside from the current price. This is not investment advice.
What is BioNTech's StockVane Quant Rating?
The StockVane Momentum strategy currently rates BioNTech a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
BioNTech discussion 0 comments